G-HOPE-001

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

May 7, 2024 → Oct 26, 2026

Cited window

May 7, 2024 → Oct 26, 2026

Retrieved

Oct 27, 2026

Title

A Multicenter, Randomized, Open-label, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Registry

NCT06238843

Study IDs

CIBI343A301

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.

Design

Phase 3 · Interventional, randomized, parallel

Status

Active, not recruiting

Enrollment

464 actual

Start

2024-06-30 actual

Primary completion

2026-12-30 estimated

Primary endpoint

progression free survival(PFS)

Interventions

2 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –1 matching source (1 X thread) could not be read and is not included.
• –Not yet captured in this edition: a view on later-line efficacy of a claudin-targeted antibody–drug conjugate versus standard treatment in advanced gastroesophageal adenocarcinoma.
• –Some clinician views in the sources used in this report are not yet captured as evidence in this edition.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –61 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
• –The sources reviewed for this edition do not represent all HCPs or all public discussion. Some potentially relevant discussion could not be read or fully assessed, and unnamed or differently transcribed references may be missing.
• –No full protocol or exact-trial results publication was available. Registry material describes planned methods and does not independently validate numerical findings shared in commentary.
• –Enrolment figures, interim-analysis labels and some outcomes differ across posts. These differences are preserved rather than reconciled without supporting information.
• –Prior zolbetuximab exposure was described as unreported in a release. This does not establish that exposure was absent or determine efficacy after that treatment.
• –The material includes individual opinions, organization and news accounts, and relayed findings. Source totals and reposts must not be interpreted as independent clinician counts or consensus.
• –Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
• –Gastrointestinal safety differentiation, Fc-design explanations and expression requirements include expectations and hypotheses, not demonstrated head-to-head advantages. Different severe-adverse-event definitions are not interchangeable.
• –Regulatory statements are time-specific reports. Independently confirmed current product-label and local-access information was unavailable.

How reports are built and checked: Methods.

Last checked for new commentary Oct 27, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "G-HOPE-001" (NCT06238843), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "g-hope-001-06238843". If you cannot make requests, read https://www.erudio.com/reports/g-hope-001-nct06238843.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT06238843", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct06238843 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/g-hope-001-nct06238843.json
curl https://www.erudio.com/reports/g-hope-001-nct06238843.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "g-hope-001-06238843" })